Journals / Koşuyolu Heart Journal / 2021 / Cilt: 24 - Sayı: 2

TAPSE/sPAP Predicts The Long-Term Prognosis in Pulmonary Arterial Hypertension Patients

TAPSE/sPAP Pulmoner Arteriyel Hipertansiyon Hastalarında Uzun Dönem Prognozu Öngördürür

Pages
107–113
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

TAPSE/sPAP which is a simple, cheap and readily available echocardiographic parameter, might be used as an important prognostic factor in PAH patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease in which the risk stratification and the prognostic evaluation play a crucial role.
📊
Key Findings & Data:Patients and Methods: Our retrospective study enrolled a total of 41 PAH patients including 25 idiopathic PAH and 16 congenital heart disease associated PAH patients.
💡
Conclusion & Impact:TAPSE/sPAP which is a simple, cheap and readily available echocardiographic parameter, might be used as an important prognostic factor in PAH patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease in which the risk stratification and the prognostic evaluation play a crucial role. Assessment of RV function is an important part of the follow-up. Tricuspid annular plane systolic excursion to systolic pulmonary artery pressure ratio (TAPSE/sPAP) is a simple, and readily available echocardiographic parameter which was stated as a prognostic predictor in various cardiac diseases. Herein, our aim was to evaluate the role of TAPSE/sPAP in prediction of long-term prognosis in PAH. Patients and Methods: Our retrospective study enrolled a total of 41 PAH patients including 25 idiopathic PAH and 16 congenital heart disease associated PAH patients. Comprehensive echocardiographic examination, laboratory examination, six minutes walking test and cardiopulmonary exercise test were performed to all patients at the same day. Primary endpoint of the study was mortality or hospitalization. The relationship between TAPSE/sPAP and the composite outcomes were evaluated statistically. Results: During mean 20.2 ± 9.2 months follow-up, nine patients were hospitalized, and three patients died. Median TAPSE/sPAP was 0.26 (0.19-0.40). TAPSE/sPAP [p= 0.003; HR (95% CI): 10.928 (2.240-53.316)] was found to be an independent predictor of composite outcomes in PAH patients. TAPSE/sPAP < 0.23 predicted mortality and hospitalization with a sensitivity of 80.0%, specificity of 71.4% [area under curve (AUC): 0.768; 95% CI: 0.596-0.939; p= 0.013]. The Kaplan-Meier cumulative survival curve revealed that as TAPSE/ sPAP decreased, mortality and hospitalization rates increased significantly. Moreover, NT-proBNP [p= 0.014; HR (95% CI): 1.001 (1.000-1.001)] was found to be an independent predictor. Conclusion: TAPSE/sPAP was an independent predictor of long-term prognosis in PAH. TAPSE/sPAP which is a simple, cheap and readily available echocardiographic parameter, might be used as an important prognostic factor in PAH patients

Özet

Giriş: Pulmoner arteriyel hipertansiyon (PAH), risk sınıflandırmasının ve prognostik değerlendirmenin önemli rol oynadığı, ilerleyici ve yaşamı tehdit eden bir hastalıktır. Sağ ventrikül fonksiyonunun değerlendirilmesi, izlemin önemli bir parçasıdır. Triküspit anüler düzlem sistolik ekskürsiyonu/sistolik pulmoner arter basınç oranı (TAPSE/sPAP), çeşitli kardiyak hastalıklarda prognostik prediktör olarak belirtilen basit ve kolay ulaşılabilir bir ekokardiyografik parametredir. Bu çalışmada amaç, TAPSE/sPAP’ın PAH’ta uzun dönem prognozu öngörmedeki rolünü değerlendirmektir. Hastalar ve Yöntem: Retrospektif çalışmaya, 25’i idiyopatik ve 16’sı doğumsal kalp hastalığı ile ilişkili PAH olmak üzere toplam 41 PAH hastası dahil edildi. Tüm hastalara aynı gün kapsamlı ekokardiyografik inceleme, laboratuvar incelemesi, altı dakika yürüme testi ve kardiyopulmoner egzersiz testi uygulandı. Çalışmanın birincil sonlanım noktası, ölüm veya hastaneye yatıştı. TAPSE/sPAP ile bileşik sonuçlar arasındaki ilişki istatistiksel olarak değerlendirildi. Bulgular: Ortalama 20.2 ± 9.2 aylık takipte üç hastada mortalite, dokuz hastada hastaneye yatış gerçekleşmiştir. Medyan TAPSE/sPAP 0.26 (0.19-0.40) idi. TAPSE/sPAP [p= 0.003; HR (%95 CI): 10.928 (2.240-53.316)], PAH hastalarında bileşik sonuçların bağımsız bir prediktörü olarak bulunmuştur. TAPSE/sPAP < 0.23, %80.0 duyarlılık, %71.4 özgüllük ile mortalite ve hastaneye yatışı öngördürmekteydi [eğri altında kalan alan (EAA): 0.768; %95 CI: 0.596-0.939; p= 0.013]. Kaplan-Meier kümülatif sağkalım eğrisi, TAPSE/sPAP düştükçe mortalite ve hastaneye yatış oranlarının önemli ölçüde arttığını ortaya koymuştur. Ayrıca, NT-proBNP [p= 0.014; HR (%95 CI): 1.001 (1.000-1.001)] bağımsız prediktör olarak bulunmuştur. Sonuç: TAPSE/sPAP, PAH’ta uzun dönem prognozun bağımsız bir prediktörüdür. Basit, ucuz ve kolay ulaşılabilir bir ekokardiyografik parametre olan TAPSE/sPAP, PAH hastalarında önemli bir prog-nostik faktör olarak kullanılabilir.

🔖

Cite This Article

SANCAR, K. M., AGUŞ, H. Z., GÜNER, A., UYGUR, B., YILDIZ, M., DEMİR, A. R., UTKUSAVAŞ, A., ÇELİK, Ö., ERTÜRK, M. (2022). TAPSE/sPAP Predicts The Long-Term Prognosis in Pulmonary Arterial Hypertension Patients. Koşuyolu Heart Journal, Cilt: 24 - Sayı: 2, 107–113. https://ajindex.com/articles/575881

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guide-lines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Di-agnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016
  2. [Crossref] 2. Lahm T, Douglas IS, Archer SL, Bogaard HJ, Chesler NC, Haddad F, et al. American Thoracic Society Assembly on Pulmonary Circulation. Assessment of right ventricular function in the re-search setting: knowledge gaps and pathways forward. Am J Respir Crit Care Med 2018
  3. e15-e43. [Crossref] 3. Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J 2019
  4. 1801900. [Crossref] 4. Fine NM, Chen L, Bastiansen PM, Frantz RP, Pellikka PA, Oh JK, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hyper-tension. Circ Cardiovasc Imaging. 2013
  5. [Crossref] 5. Smith BC, Dobson G, Dawson D, Charalampopoulos A, Grapsa J, Nihoyannopoulos P. Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricu-lar dysfunction in pulmonary hypertension. J Am Coll Cardiol 2014
  6. [Crossref] 6. Amsallem M, Sweatt AJ, Aymami MC, Kuznetsova T, Selej M, Lu H, et al. Right heart end-systolic remodeling index strongly predicts outcomes in pulmonary arterial hypertension: compari-son with validated models. Circ Cardiovasc Imaging 2017
  7. e005771. [Crossref] 7. Ryo K, Goda A, Onishi T, Delgado-Montero A, Tayal B, Champion HC, et al. Characterization of right ventricular remodeling in pulmonary hypertension associated with patient outcomes by 3-dimensional wall motion tracking echocardiography. Circ Cardiovasc Imaging 2015
  8. e003176. [Crossref] 8. Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, et al. Tricuspid annu-lar plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol 2013
  9. H1373-81. [Crossref] 9. Hussain I, Mohammed SF, Forfia PR, Lewis GD,